Lipeng Xu

Dr. Lipeng Xu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2016 in Scientific Reports
Verified
Journal Article
Open access
YYYali Yang
Yali Yang
HYHui Yan
Hui Yan
MJMei Jing
Mei Jing
ZZZaijun Zhang
Zaijun Zhang
GZGaoxiao Zhang
Gaoxiao Zhang
LXLipeng Xu
Lipeng Xu
Andrographolide is a traditional herb medicine, widely used in Asia for conditions involving inflammation. The andrographlide-lipoic acid conjugate, AL-1, has been found being able to alleviate inflammation in our previous reports. Although the anti-inflammatory activity of AL-1 contributes to its cytoprotective effects, whether AL-1 can improve inflammatory bowel disease (IBD) and the underlying mechanisms of its action remain largely unknown. In this study, we investigated the anti-inflammatory effects of AL-1 in C57BL/6 mice with trinitrobenzenesulfonic acid (TNBS)-induced colitis. The body weight loss and length change of colon after TNBS instillation were more severe than those in normal mice. AL-1 treatment led to significant reductions in disease activity index (DAI), macroscopic score and colon mucosa damage index (CMDI) associated with TNBS administration. AL-1 inhibited the inflammatory response via lowering the level of inflammatory cytokines and myeloperoxidase (MPO) activity. AL-1 attenuated the expression of p-p65, p-IκBα and COX-2 in the colitis mice. The alleviation of colon injury by AL-1 treatment was also evidenced by the increased expression of PPAR-γ. These results indicated that AL-1 could protect intestinal tract from the injury induced by TNBS in mice, suggesting that AL-1 may have potential in treatment for IBD.

7 October 2019 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
MJMei Jing
Mei Jing
YWYuqiang Wang
Yuqiang Wang
LXLipeng Xu
Lipeng Xu
Trinitrobenzenesulfonic acid (TNBS) and dextran sodium sulfate (DSS) are commonly used to induce experimental murine ulcerative colitis (UC). Our recent study has demonstrated that a novel andrographolide derivative, AL-1, ameliorated TNBS-induced colitis in mice. However, the effect of AL-1 on DSS-induced murine colitis and the underlying mechanisms are yet unknown. In the present study, we aimed to investigate the therapeutic potential of AL-1 against DSS-induced UC in mice and to define its mechanisms of action. Oral administration of AL-1 attenuated body weight loss, reduced colon length shortening, lowered the disease activity index score, and alleviated colon histological damage. AL-1 significantly inhibited myeloperoxidase activity and suppressed immune inflammatory responses in colonic tissues. Moreover, AL-1 reversed DSS-altered expression of inflammatory cytokines in DSS-induced colitis mice. Importantly, the efficacy of 45 mg/kg of AL-1 was higher than that of 100 mg/kg of the positive control drugs 5-aminosalicylic acid and mesalazine. AL-1 decreased lipopolysaccharide-induced generation of reactive oxygen species and nitric oxide in cultured macrophages in vitro; it also reversed the altered expression of inflammatory cytokines. In both in vivo and in vitro studies, Western blot analysis revealed that AL-1 reduced the expression of phosphorylated NF-κB p65 and IκBα, downregulated the expression of iNOS and COX-2, and attenuated the expression of phosphorylated p38 mitogen-activated protein kinase (MAPK), ERK, and JNK. In conclusion, AL-1 alleviated DSS-induced murine colitis by inhibiting activation of the NF-κB and MAPK signaling pathways. Our data suggest that AL-1 could be a potential new treatment for UC.

10 April 2015 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
YLYongmei Li
Yongmei Li
HYHui Yan
Hui Yan
ZZZaijun Zhang
Zaijun Zhang
GZGaoxiao Zhang
Gaoxiao Zhang
YSYewei Sun
Yewei Sun
LXLipeng Xu
Lipeng Xu

5 May 2024 in Toxicon
Verified
Journal Article
Closed access
YLYupei Liao
Yupei Liao
XXXiaoqing Xie
Xiaoqing Xie
CZChu Zhang
Chu Zhang
HZHaijing Zhong
Haijing Zhong
LSLuchen Shan
Luchen Shan
LXLipeng Xu
Lipeng Xu

1 January 2020 in Life Sciences
Verified
Journal Article
Closed access
NJNan Jiang
Nan Jiang
YWYuke Wei
Yuke Wei
YCYun Cen
Yun Cen
LSLuchen Shan
Luchen Shan
ZZZaijun Zhang
Zaijun Zhang
LXLipeng Xu
Lipeng Xu

1 January 2024 in Toxicology Research
Verified
Journal Article
Closed access
PDF file
CZChu Zhang
Chu Zhang
YLYupei Liao
Yupei Liao
TLTangjia Li
Tangjia Li
HZHai-Jing Zhong
Hai-Jing Zhong
LSLuchen Shan
Luchen Shan
LXLipeng Xu
Lipeng Xu
The 2022 US Cancer Statistics show that breast cancer is one of the most common cancers in women. Epidemiology has shown that adding flavonoids to the diet inhibits cancers that arise in particular women, such as cervical cancer, ovarian cancer, and breast cancer. Although there have been research reports on apigenin (API) and breast cancer, its anti-tumor effect and potential mechanism on breast cancer have not yet been clarified. Therefore, in this study, we used 4T1 cells and a 4T1 xenograft tumor mouse model to investigate the antitumor effect of API on breast cancer and its underlying mechanism. In vitro, we used MTT, transwell, staining, and western blotting to investigate the inhibitory effect of apigenin on 4T1 and the underlying molecular mechanism. In vivo by establishing a xenograft tumor model, using immunohistochemistry, and flow cytometry to study the inhibitory effect of apigenin on solid breast tumors and its effect on the tumor immune microenvironment. The results showed that API can induce breast cancer cell apoptosis through the PI3K/AKT/Nrf2 pathway and can improve the tumor immune microenvironment in mice with breast tumors, thereby inhibiting the growth of breast cancer. Thus, API may be a promising agent for breast cancer treatment.